Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
NEUP
NEUP
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
NEUP News
Merck Halts Alzheimer’s Drug Trial MK-1167 Due to Poor Performance
6d ago
stocktwits
Merck Halts Development of Alzheimer's Drug MK-1167
6d ago
seekingalpha
Neuphoria Therapeutics in Talks for Possible Merger with Scancell Holdings
Jun 26 2026
Newsfilter
Neuphoria Urges Shareholders to Support Director Nominees for Maximum Value
Dec 08 2025
Newsfilter
Nasdaq Rises 1%; Procter & Gamble Reports Positive Earnings
Oct 24 2025
Benzinga
Tuesday's Major Stock Market Highlights: Morning News Summary!
Oct 21 2025
TipRanks
What Caused Neuphoria Therapeutics Stock (NEUP) to Drop 65% Today?
Oct 21 2025
TipRanks
Neuphoria Therapeutics Shares Progress on AFFIRM-1 Phase 3 Trial Assessing BNC210 for Treating Acute Social Anxiety Disorder
Oct 20 2025
Newsfilter
Neuphoria Therapeutics Inc. Sees Decrease in Annual Loss
Sep 30 2025
NASDAQ.COM
IMRX Rises on Pancreatic Cancer Findings, PEPG Achieves DM1 Splicing Correction Milestone, CLPT Under Observation
Sep 25 2025
NASDAQ.COM
Maxim Group Reaffirms Buy Rating for Neuphoria Therapeutics and Increases Price Target to $35
Sep 11 2025
Benzinga
Neuphoria Therapeutics Achieves Target Enrollment for Phase 3 AFFIRM-1 Study of BNC-210 in Treating Social Anxiety Disorder (SAD)
Sep 04 2025
Newsfilter
HC Wainwright & Co. Affirms Buy Rating for Neuphoria Therapeutics, Keeps $21 Price Target Intact
Aug 26 2025
Benzinga
Neuphoria to Present at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting
May 27 2025
Newsfilter
Neuphoria Therapeutics Inc. Reports Q1 2025 Progress and Upcoming Milestones for BNC210 and MK-1167 Programs
May 20 2025
NASDAQ.COM
Neuphoria Provides First Quarter 2025 Business Updates
May 20 2025
Newsfilter
Show More News
